EuDKA is a recognized adverse effect of SGLT2 inhibitors with an incidence rate of 0.1% to 0.3%.[5] EuDKA has similar characteristics as diabetic ketoacidosis, including ketonuria/ketonemia, arterial pH <7.3, serum bicarbonate <15 mEq/L, and an increased anion gap metabolic acidosis. Here, SLC5A2 is linked to diabetic ketoacidosis.